Cagrilintide (AM833) Long acting amylin analog. Beta cells make TWO hormones: insulin and amylin. Amylin slows stomach emptying and reduces appetite. Cagrilintide is a long acting synthetic amylin designed for once weekly dosing Novo Nordisk shares higher on positive Phase 3 trial results for obesity drug Cagrilintide NYSE:NVO PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar What is the pipeline for future medications for obesity? International Journal of Obesity Were entering a new chapter in weight and metabolic health. While GLP 1s have been in the spotlight, researchers are finding that amylin agonists may offer similar levels of weight loss and were Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine